(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells
Safety and Activity of a Conditionally Active cLAG3-IL2
Introduction
IL-2 is a powerful cytokine, but it has seen limited use in the treatment of cancer due to itstoxicity. Additional strategies to address these limitations are still needed.
• Our (Bonum) proprietary dual-binding antibody (DBA)-based platform allows the creation of conditionally active immunocytokines.
• Conditionally active LAG3-IL2 (cLAG3-IL2) specifically targets IL-2 to LAG-3-expressing antigen-experienced T cells while remaining inactive on the majority of IL-2R+ cells. This combines the IL-2 cis-targeting activity of a LAG3-IL2 immunocytokine when bound toLAG-3 with the “offness” of an IL-2 neutralizing antibody when unbound.
• In vitro activity of cLAG3-IL2 on reporter cell lines and LAG-3+ human T cells demonstrates conditional IL-2 signaling dependent on LAG-3 binding.
• In syngeneic mouse tumor models, cLAG3-IL2 inhibits tumor growth while avoiding clinical signs of IL-2 toxicity, even at high doses.
• cLAG3-IL2 drives the expansion and activation of tumor-specific CD8+ T without increasing peripheral IL-2R+ NK cell or T cell numbers.
![](https://cdn.prod.website-files.com/655dd3c88278aa64954052d4/667be077f8694fccb329d01f_bonum_poster_AACR2024_PD-1-Lag3_website_img01.webp)
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our modelsScientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in FranceCustomer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfactionCollaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate